Int J Food Sci. 2026 Nov 14;2026:6956918. doi: 10.1155/ijfo/6956918. eCollection 2026.
ABSTRACT
The human gastrointestinal (GI) microbiota is a complex and dynamic microbial ecosystem that plays a fundamental role in maintaining host metabolism, immune homeostasis, intestinal barrier integrity, and protection against pathogenic microorganisms. Disruption of this microbial community, known as gut dysbiosis, has been implicated in the pathogenesis of numerous GI and systemic diseases, including inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), Clostridioides difficile infection, obesity, type 2 diabetes mellitus, colorectal cancer, and nonalcoholic fatty liver disease. Although antibiotics remain indispensable for the treatment of bacterial infections, their indiscriminate use frequently disrupts gut microbial composition, reduces microbial diversity, promotes opportunistic pathogen overgrowth, and accelerates the emergence of antimicrobial resistance. These limitations have stimulated increasing interest in microbiota-targeted interventions as safer and more sustainable therapeutic strategies. Probiotics and prebiotics have emerged as promising approaches for restoring gut microbial homeostasis through complementary mechanisms. Probiotics inhibit pathogen colonization, enhance intestinal barrier function, produce antimicrobial metabolites, and modulate host immune responses. Prebiotics selectively stimulate the growth and metabolic activity of beneficial microorganisms, promoting the production of short-chain fatty acids (SCFAs) that support intestinal and systemic health. Increasing evidence from experimental studies, randomized clinical trials, and meta-analyses demonstrates that these microbiota-directed interventions can reduce antibiotic-associated diarrhea, improve symptoms of IBD and IBS, enhance Helicobacter pylori eradication, decrease recurrence of C. difficile infection, and contribute to the management of several metabolic disorders. Despite these promising findings, important challenges remain regarding strain specificity, optimal dosage, treatment duration, product standardization, regulatory oversight, and interindividual variability in treatment response. Emerging advances in metagenomics, metabolomics, artificial intelligence, and precision medicine are facilitating the development of personalized microbiome-based therapies that may further enhance clinical outcomes. This review critically summarizes the current understanding of GI microbiota dysbiosis, discusses the mechanisms through which probiotics and prebiotics restore microbial balance, evaluates their clinical applications as alternatives or adjuncts to antibiotic therapy, and highlights existing challenges and future research directions for microbiome-based therapeutics.
PMID:43034624 | PMC:PMC13769041 | DOI:10.1155/ijfo/6956918